Polycystic Ovary Syndrome (PCOS) – High‑Yield Study Guide for Medical Students

Definition

Polycystic Ovary Syndrome (PCOS) is a common, chronic, heterogeneous endocrine disorder of reproductive-aged women characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, after exclusion of other etiologies. PCOS is a diagnosis of exclusion and is associated with significant metabolic and cardiometabolic comorbidity.

The most widely used diagnostic framework is the Rotterdam criteria (2003), which define PCOS when two out of three of the following are present, after exclusion of other causes:

Oligo- or anovulation (typically menstrual cycles >35 days or <8 cycles/year)
Clinical and/or biochemical hyperandrogenism (hirsutism, acne, androgenic alopecia; elevated total or free testosterone, or free androgen index)
Polycystic ovarian morphology (PCOM) on ultrasound: ≥20 follicles per ovary (2–9 mm) and/or ovarian volume >10 mL (transvaginal, high-frequency probe; thresholds may vary by guideline and technology)

Epidemiology

PCOS is one of the most common endocrine disorders in women of reproductive age, with a prevalence of approximately 8–13% depending on the diagnostic criteria and population studied. Prevalence rises when broader criteria (Rotterdam) are used and in populations with higher rates of obesity and insulin resistance.

Onset typically occurs around menarche to early adulthood.
There is marked ethnic variation in phenotype (e.g., more prominent hirsutism in Mediterranean or South Asian populations, higher metabolic risk in South Asians).
PCOS is strongly associated with metabolic syndrome, impaired glucose tolerance, type 2 diabetes, dyslipidemia, and obesity.

Pathophysiology

PCOS is multifactorial, involving a complex interplay of genetic predisposition and environmental factors, leading to hyperandrogenism, chronic anovulation, and insulin resistance.

Key Pathophysiologic Mechanisms

Hypothalamic–pituitary–ovarian (HPO) axis dysregulation
- Increased GnRH pulse frequency favors LH over FSH secretion.
- Elevated LH stimulates theca cells to produce excess androgens (androstenedione, testosterone).
- Relatively low/normal FSH impairs granulosa cell aromatization of androgens to estrogens, contributing to follicular arrest.
Ovarian factors
- Theca cell hyperplasia and increased CYP17A1 activity increase androgen synthesis.
- Excess intraovarian androgens lead to follicular arrest at the small antral stage, resulting in multiple small follicles and anovulation.
Insulin resistance and hyperinsulinemia
- Many patients exhibit intrinsic insulin resistance independent of BMI.
- Hyperinsulinemia synergizes with LH on theca cells, amplifying androgen production.
- Insulin suppresses hepatic sex hormone–binding globulin (SHBG) synthesis, increasing free androgens.
- Insulin resistance also drives increased risk of impaired glucose tolerance, type 2 diabetes, and metabolic syndrome.
Adipose tissue and obesity
- Visceral adiposity worsens insulin resistance and hyperinsulinemia.
- Adipokines and low-grade inflammation further disturb HPO axis function.
Genetic and environmental factors
- Familial clustering suggests polygenic inheritance.
- In utero androgen exposure and lifestyle/environmental factors contribute to phenotype expression.

Clinical Presentation

Presentation is heterogeneous and may vary across life stages (adolescence vs adult vs perimenopause). Many patients are identified during evaluation for menstrual irregularities, hirsutism, acne, infertility, or metabolic abnormalities.

Reproductive and Menstrual Features

Oligomenorrhea or amenorrhea
- Cycles >35 days, <8 menses per year, or amenorrhea >3 months.
- Some patients have apparent regular cycles but underlying anovulation (e.g., infertility despite apparently regular menses).
Subfertility/infertility
- Chronic anovulation is a major cause of infertility in PCOS.
- Increased risk of early pregnancy loss may be present.

Hyperandrogenic Features

Hirsutism
- Terminal hair in a male-pattern distribution: face (upper lip, chin), chest, abdomen, back, thighs.
- Often quantified using the modified Ferriman-Gallwey (mFG) score.
Acne and seborrhea
Androgenic alopecia (female-pattern hair loss)

Metabolic and Cardiovascular Features

Overweight/obesity, particularly central/visceral adiposity
Insulin resistance and hyperinsulinemia
Impaired glucose tolerance (IGT) and type 2 diabetes mellitus
Dyslipidemia: elevated triglycerides, low HDL, sometimes elevated LDL
Features of metabolic syndrome
Increased long-term risk of hypertension, nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease

Gynecologic and Other Features

Chronic anovulation leads to unopposed estrogen and increased risk of endometrial hyperplasia and endometrial carcinoma.
Abnormal uterine bleeding patterns may occur.
Psychological comorbidities are common: anxiety, depression, body image disturbance, and reduced quality of life.
Sleep disturbances, including increased prevalence of obstructive sleep apnea, especially in obese patients.

Physical Examination

General: BMI, waist circumference, blood pressure.
Skin:
- Hirsutism (mFG score).
- Acne, seborrhea, androgenic alopecia.
- Acanthosis nigricans as a marker of insulin resistance.
- Skin tags (acrochordons).
Signs of virilization (deep voice, clitoromegaly, marked muscle mass) suggest an alternative diagnosis (e.g., androgen-secreting tumor, CAH) and should prompt urgent evaluation.

Diagnosis

PCOS is a clinical diagnosis supported by laboratory and imaging findings, made after exclusion of other causes of hyperandrogenism and ovulatory dysfunction.

Diagnostic Criteria

The Rotterdam criteria (2003) are most widely used and endorsed by many international guidelines:

Diagnosis requires ≥2 of 3 features:
- Oligo- or anovulation
- Clinical and/or biochemical hyperandrogenism
- Polycystic ovarian morphology (PCOM) on ultrasound
Other etiologies must be excluded.

Alternative criteria (e.g., NIH 1990, AE-PCOS Society) are more restrictive and require hyperandrogenism plus ovulatory dysfunction.

Essential Laboratory Evaluation

Initial investigations should assess for hyperandrogenemia, rule out mimics, and screen for metabolic complications.

Pregnancy test (beta-hCG) in amenorrheic/oligomenorrheic patients.
Androgen assessment:
- Total testosterone (preferably measured via reliable assay).
- Free testosterone or calculated free androgen index (FAI), if available.
- DHEA-S to assess adrenal contribution.
- Markedly elevated testosterone or DHEA-S suggests androgen-secreting tumor rather than PCOS.
Gonadotropins and ovarian hormones:
- LH and FSH (LH often elevated, LH:FSH ratio >2, but not required for diagnosis).
- Prolactin to exclude hyperprolactinemia.
- TSH to exclude thyroid disease.
- Estradiol as needed for broader evaluation of amenorrhea.
Screen for nonclassical congenital adrenal hyperplasia (NCCAH):
- Morning 17-hydroxyprogesterone; if elevated, consider ACTH stimulation test.
Metabolic screening:
- Fasting plasma glucose and/or 75 g oral glucose tolerance test (OGTT) (recommended by many guidelines as the most sensitive test for dysglycemia in PCOS).
- Fasting lipid profile: triglycerides, HDL, LDL, total cholesterol.
- Liver function tests if NAFLD is suspected.
Additional tests as indicated based on phenotype (e.g., 24-h urinary free cortisol or late-night salivary cortisol if Cushing syndrome is suspected).

Imaging

Transvaginal pelvic ultrasound (preferred in sexually active women; transabdominal in virginal or adolescents):
- Polycystic ovarian morphology (PCOM) is defined (per recent guidelines with modern high-frequency probes) as:
  - ≥20 follicles per ovary, measuring 2–9 mm in diameter, and/or
  - Ovarian volume >10 mL in at least one ovary.
- PCOM is common and not specific to PCOS; the scan supports but does not alone establish diagnosis.

Differential Diagnosis

Important conditions to exclude before labeling PCOS:

Physiologic pubertal anovulation (in adolescents within the first 1–2 years post-menarche).
Pregnancy.
Thyroid dysfunction (hypo- or hyperthyroidism).
Hyperprolactinemia.
Nonclassical congenital adrenal hyperplasia (NCCAH) (21-hydroxylase deficiency).
Cushing syndrome.
Androgen-secreting tumors (ovarian or adrenal) – rapid onset, severe virilization, markedly elevated androgens.
Premature ovarian insufficiency and other primary ovarian disorders.
Hypothalamic amenorrhea (e.g., related to low weight, stress, excessive exercise).

Management

Management is individualized and depends on the patient’s main concerns (e.g., cycle regulation, hirsutism/acne, fertility, metabolic health, long-term risk reduction). Multidisciplinary care (gynecology, endocrinology, dermatology, dietetics, psychology) is often optimal.

General Principles

Treat symptoms and priorities: menstrual irregularity, hyperandrogenism, infertility, metabolic risk.
Address lifestyle factors and weight management in all patients, regardless of BMI.
Provide long-term follow-up for metabolic and cardiovascular risk, and endometrial protection in anovulatory women.

Lifestyle and Non‑pharmacologic Management

Weight loss (for overweight/obese patients)
- Modest weight loss (5–10% of body weight) can significantly improve ovulatory function, insulin sensitivity, and hyperandrogenic symptoms.
- Calorie restriction with a sustainable pattern (e.g., Mediterranean-style diet) and increased physical activity.
Exercise
- Both aerobic and resistance training improve insulin sensitivity, body composition, and metabolic parameters.
Behavioral and psychological support
- Screen for depression and anxiety; consider counseling or CBT.
Cosmetic measures
- For hirsutism: shaving, waxing, depilatory creams, laser hair removal, electrolysis.
- Topical eflornithine for facial hirsutism can be considered adjunctively.

Pharmacologic Management (Non‑fertility Focus)

1. Menstrual Irregularity and Endometrial Protection

Combined oral contraceptives (COCs) are first-line in women not seeking pregnancy.
- Provide cycle regulation and endometrial protection.
- Reduce ovarian androgen production by suppressing LH and increase SHBG, lowering free testosterone.
- Use low-dose ethinyl estradiol preparations; choose progestin with lower androgenic activity.
Cyclic progestins
- For women who cannot or do not wish to use estrogen-containing contraception.
- Administer oral progestin (e.g., medroxyprogesterone acetate 10 mg daily for 10–14 days) every 1–3 months to induce withdrawal bleeding and protect the endometrium.
Levonorgestrel-releasing intrauterine system (LNG-IUS)
- Provides local progestin effect with excellent endometrial protection and contraception.

2. Hyperandrogenism (Hirsutism, Acne)

Combined oral contraceptives
- First-line pharmacologic therapy for hirsutism and acne in PCOS.
- Improvement is gradual and requires at least 6 months.
Antiandrogens (usually adjunct to COCs; avoid in pregnancy due to teratogenicity)
- Spironolactone (e.g., 50–100 mg twice daily): androgen receptor antagonist and 5α-reductase inhibitor; monitor potassium and renal function.
- Finasteride or dutasteride: 5α-reductase inhibitors, used less commonly and off-label in women; require strict contraception.
- Flutamide: effective but limited by hepatotoxicity; rarely first-line.
Topical therapies
- Eflornithine cream for facial hirsutism slows hair growth; often combined with laser hair removal.
Dermatologic therapies for acne as needed (topical retinoids, benzoyl peroxide, oral antibiotics, isotretinoin with appropriate contraception).

3. Metabolic Abnormalities

Metformin
- Improves insulin sensitivity, lowers insulin levels, and may modestly lower androgens.
- Useful in women with impaired glucose tolerance or type 2 diabetes, or when COCs are contraindicated.
- May improve menstrual regularity but is less effective than COCs for hyperandrogenic symptoms.
Other antidiabetic agents
- In some patients, especially with T2DM, GLP-1 receptor agonists or SGLT2 inhibitors may be used for weight and glycemic control, guided by diabetes guidelines.
Lipid-lowering therapy (e.g., statins) and antihypertensives according to standard cardiovascular risk guidelines if dyslipidemia or hypertension is present.

Management When Fertility Is Desired

For patients seeking pregnancy, management focuses on restoring ovulation and optimizing metabolic health.

Preconception optimization
- Promote weight loss in overweight/obese patients; even modest weight reduction improves ovulation and pregnancy rates.
- Address smoking, alcohol, and comorbidities (e.g., diabetes control, blood pressure).
- Folic acid supplementation per preconception guidelines.
First-line ovulation induction
- Guidelines increasingly recommend letrozole (an aromatase inhibitor) as first-line pharmacologic ovulation induction in PCOS due to higher live birth and ovulation rates compared with clomiphene citrate.
- Clomiphene citrate remains a widely used alternative or second-line agent in some settings.
Metformin
- Can be used as adjunct in women with insulin resistance or IGT/T2DM.
- May improve ovulatory response in some clomiphene-resistant individuals.
Second-line options
- Gonadotropin therapy (FSH with or without LH) with careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy.
- Laparoscopic ovarian drilling in clomiphene-resistant PCOS, usually in select cases; can reduce androgen production and restore ovulation but carries surgical risks and potential for adhesion formation or diminished ovarian reserve.
Assisted reproductive technologies (ART)
- In vitro fertilization (IVF) for those who do not respond to ovulation induction or with additional infertility factors.

Long-term Monitoring and Risk Reduction

Metabolic monitoring
- Periodic assessment of glucose tolerance (OGTT or fasting glucose/HbA1c) guided by baseline risk and guidelines.
- Regular lipid profiles and blood pressure checks.
- Screen for NAFLD when indicated (e.g., LFTs, ultrasound).
Endometrial protection
- Ensure regular withdrawal bleeding (through spontaneous cycles, COCs, cyclic progestin, or LNG-IUS).
- Investigate abnormal uterine bleeding; consider endometrial biopsy if risk factors for hyperplasia or carcinoma.
Mental health and quality of life
- Regular screening for depression, anxiety, and eating disorders.
- Offer psychological support when needed.

Key Clinical Pearls for Exams and Practice

PCOS is a diagnosis of exclusion: always rule out pregnancy, thyroid disease, hyperprolactinemia, NCCAH, Cushing syndrome, and androgen-secreting tumors in women with hyperandrogenism and/or menstrual irregularities.
The most widely used diagnostic framework is the Rotterdam criteria: any two of oligo/anovulation, hyperandrogenism, and polycystic ovarian morphology, after exclusion of other causes.
Insulin resistance is central to PCOS pathophysiology and contributes to both hyperandrogenism and metabolic risk.
Endometrial hyperplasia and carcinoma risk is increased due to chronic anovulation and unopposed estrogen; ensure regular endometrial shedding via COCs, cyclic progestin, or LNG-IUS.
Combined oral contraceptives are first-line for menstrual irregularity and hyperandrogenic symptoms in women not seeking pregnancy.
Letrozole is increasingly considered the first-line agent for ovulation induction in infertility due to PCOS; clomiphene is an established alternative.
Metformin is useful for insulin resistance and dysglycemia, and can help menstrual regularity, but is less effective than COCs for cosmetic hyperandrogenism.
Rapid onset of severe virilization (deep voice, clitoromegaly, rapid muscle mass increase) or very high androgen levels should trigger evaluation for androgen-secreting tumors.
Adolescents: diagnostic labels should be applied cautiously; normal pubertal anovulatory cycles and transient acne/hirsutism can mimic PCOS; guidelines recommend using stricter criteria and time since menarche.
PCOS is a lifelong condition; management shifts from cycle control and cosmetic concerns to fertility and then to long-term cardiometabolic risk reduction.

High-Yield Exam Pointers

Board-style questions often test recognition of obese young woman with irregular menses, infertility, and hirsutism, with labs showing elevated LH, normal FSH, and signs of insulin resistance.
Know the link between PCOS and type 2 diabetes, metabolic syndrome, and endometrial carcinoma.
Remember that weight loss alone can restore ovulation in many patients.
Differentiate PCOS from NCCAH (elevated 17-hydroxyprogesterone) and androgen-secreting tumors (very high androgens, rapid virilization).